砥砺前行，从三大权威指南看T-DXd在HER2阳性晚期胃癌中强势发展( 四 ) _健康小知识

专家简介

文章图片
朱晓东
复旦大学附属肿瘤医院肿瘤内科主任医师，硕士研究生导师
主要从事消化道肿瘤的综合治疗，研究方向为消化道肿瘤耐药机制及疗效预测
主持完成有复旦青年基金、上海市自然科学基金、合作完成数项国家自然基金，并参与完成多个国家重大项目
学术任职：
中国抗癌协会肿瘤靶向治疗专业委员会委员
上海市抗癌协会遗传性消化道肿瘤专业委员会副主任委员
上海市抗癌协会肿瘤生物治疗专业委员会常务委员
上海市社会医疗机构协会肿瘤学分会结直肠专委会副主任委员
中国宋庆龄基金会肿瘤医疗及产学研联盟理事
中国医药教育协会腹部肿瘤专业委员会委员
中国抗癌协会肿瘤营养与支持治疗专业委员会肿瘤营养化疗学组委员
上海市抗癌协会胃肠肿瘤专业委员会委员
上海市抗癌协会癌症康复与姑息治疗专业委员会（CRPC）委员
AnnalsofOncologyExcerptsChinaEdition(GITumors)编委
参考文献：
[1]SungH,FerlayJ,SiegelRL,etal.GlobalCancerStatistics2020:GLOBOCANEstimatesofIncidenceandMortalityWorldwidefor36Cancersin185Countries.CACancerJClin.2021May;71(3):209-249.
[2]BangYJ,VanCutsemE,FeyereislovaA,etal.TrastuzumabincombinationwithchemotherapyversuschemotherapyalonefortreatmentofHER2-positiveadvancedgastricorgastro-oesophagealjunctioncancer(ToGA):aphase3,open-label,randomisedcontrolledtrial.Lancet.2010Aug28;376(9742):687-97.
[3]中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会（CSCO）胃癌诊疗指南2022[M].北京:人民卫生出版社,2022.
[4]NCCNGastricCancer.2022V2
[5]LordickF,CarneiroF,CascinuS,etal.Gastriccancer:ESMOClinicalPracticeGuidelinefordiagnosis,treatmentandfollow-up.AnnOncol.2022Jul29:S0923-7534(22)01851-8.
[6]LiJ,QinS,XuJ,etal.Randomized,Double-Blind,Placebo-ControlledPhaseIIITrialofApatinibinPatientsWithChemotherapy-RefractoryAdvancedorMetastaticAdenocarcinomaoftheStomachorGastroesophagealJunction.JClinOncol.2016May1;34(13):1448-54.
[7]KangYK,BokuN,SatohT,etal.Nivolumabinpatientswithadvancedgastricorgastro-oesophagealjunctioncancerrefractoryto,orintolerantof,atleasttwopreviouschemotherapyregimens(ONO-4538-12,ATTRACTION-2):arandomised,double-blind,placebo-controlled,phase3trial.Lancet.2017Dec2;390(10111):2461-2471.
[8]ShitaraK,BangYJ,IwasaS,etal;DESTINY-Gastric01Investigators.TrastuzumabDeruxtecaninPreviouslyTreatedHER2-PositiveGastricCancer.NEnglJMed.2020Jun18;382(25):2419-2430.
【砥砺前行，从三大权威指南看T-DXd在HER2阳性晚期胃癌中强势发展】[9]Trastuzumabderuxtecan(T-DXd;DS-8201)inpatientswithHER2–positiveadvancedgastricorgastroesophagealjunction(GEJ)adenocarcinoma:Finaloverallsurvival(OS)resultsfromarandomized,multicenter,open-label,phase2study(DESTINY-Gastric01).2022ASCOGIAbstract.242.
[10]https://www.daiichisankyo.com/media/press_release/detail/index_4078.html
[11]https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas
[12]https://clinicaltrials.gov/
[13]PengZ,LiuT,WeiJ,etal.Efficacyandsafetyofanovelanti-HER2therapeuticantibodyRC48inpatientswithHER2-overexpressing,locallyadvancedormetastaticgastricorgastroesophagealjunctioncancer:asingle-armphaseIIstudy.CancerCommun(Lond).2021Nov;41(11):1173-1182.
[14]Trastuzumabderuxtecan(T-DXd;DS-8201)inpatientswithHER2-low,advancedgastricorgastroesophagealjunction(GEJ)adenocarcinoma:ResultsoftheexploratorycohortsinthephaseII,multicenter,open-labelDESTINY-Gastric01study.2020ESMOMiniOral1422.
[15]PalleJ,RochandA,PernotS,GalloisC,Ta?ebJ,ZaananA.HumanEpidermalGrowthFactorReceptor2(HER2)inAdvancedGastricCancer:CurrentKnowledgeandFuturePerspectives.Drugs.2020Mar;80(4):401-415.